Screener
Amylyx Pharmaceuticals, Inc. AMLX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s cash & equivalents?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported cash & equivalents of $49.33M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s cash & equivalents decreased by 15.1% year-over-year, from $58.09M to $49.33M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s cash & equivalents?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s cash & equivalents has grown at a 45.8% compound annual growth rate (CAGR), from $50.19M to $226.65M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude